AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8527276 — intervention group
Group type: COMPARATOR
Intervention: Low dose cholestyramine ('Questran A')
Number of subjects: 55
Study 2611301 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocking (15-min sessions of sinusoidal oscillation, three times a day for 2 weeks)
Number of subjects: 26
Study 2611301 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocking
Number of subjects: 26
Study 786680 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (Brufen: 400 mg three times daily)
Number of subjects: 24
Study 786680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30711183 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum chloride
Number of subjects: 60
Study 30711183 — intervention group
Group type: COMPARATOR
Intervention: Electrocauterization
Number of subjects: 60
Study 28456141 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV infection
Number of subjects: 61
Study 28456141 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone use
Number of subjects: 61
Study 28456141 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesions
Number of subjects: 61
Study 28456141 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV types
Number of subjects: 61
Study 26074708 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin-doxycycline-based triple therapy with Lactobacillus casei DG (n = 71)
Number of subjects: 142
Study 26074708 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin-doxycycline-based triple therapy without Lactobacillus casei DG (n = 71)
Number of subjects: 142
Study 22884235 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 12
Study 22884235 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 12
Study 21234550 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (NIC)
Number of subjects: 49
Study 21234550 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch (PL)
Number of subjects: 49
Study 21234550 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke as normal (SM)
Number of subjects: 49
Study 19904668 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 158
Study 17095973 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitroglycerin (20 microg.kg(‐1))
Number of subjects: 100
Study 17095973 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled iloprost (2.5 microg.kg(‐1))
Number of subjects: 100
Study 15155607 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 200 micro g
Number of subjects: 48
Study 15155607 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 400 micro g
Number of subjects: 48
Study 15155607 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 800 micro g
Number of subjects: 48
Study 15155607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 12394656 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP-2 on an absorbable collagen sponge
Number of subjects: 279
Study 12394656 — intervention group
Group type: COMPARATOR
Intervention: Autogenous iliac crest bone graft
Number of subjects: 279
Study 12394656 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 279
Study 9607605 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant antileukoprotease (rALP)
Number of subjects: 0
Study 9607605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7614199 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 19
Study 7614199 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 19
Study 2198075 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (VCMP/VBAP)
Number of subjects: 386
Study 2198075 — intervention group
Group type: COMPARATOR
Intervention: Melphalan-prednisone (MP)
Number of subjects: 386
Study 369076 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclobendazole
Number of subjects: 0
Study 369076 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclobendazole (600 mg to 1200 mg)
Number of subjects: 0
Study 369076 — intervention group
Group type: COMPARATOR
Intervention: Mebendazole
Number of subjects: 0
Study 369076 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclobendazole and Mebendazole
Number of subjects: 0
Study 31361675 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcome measures (PROMs) intervention
Number of subjects: 0
Study 31449829 — intervention group
Group type: EXPERIMENTAL
Intervention: PACAP27 (10 pmol/kg/min)
Number of subjects: 18
Study 31449829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31449829 — intervention group
Group type: EXPERIMENTAL
Intervention: PACAP27
Number of subjects: 18
Study 31449829 — intervention group
Group type: EXPERIMENTAL
Intervention: PACAP38
Number of subjects: 18
Study 28412302 — intervention group
Group type: COMPARATOR
Intervention: Stage tailored intervention (ST)
Number of subjects: 1243
Study 25590980 — intervention group
Group type: EXPERIMENTAL
Intervention: VICKY
Number of subjects: 70
Study 25590980 — intervention group
Group type: COMPARATOR
Intervention: MFHP
Number of subjects: 70
Study 24227738 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of hMT
Number of subjects: 1
Study 24227738 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of hMST
Number of subjects: 1
Study 21873443 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of the bradykinin B(2) receptor antagonist, HOE‐140 (100 μg/kg)
Number of subjects: 20
Study 21873443 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 20
Study 21873443 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning
Number of subjects: 20
Study 21873443 — intervention group
Group type: EXPERIMENTAL
Intervention: HOE‐140
Number of subjects: 20
Study 19362800 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telephone reminders (ATRs)
Number of subjects: 3547
Study 19362800 — intervention group
Group type: COMPARATOR
Intervention: Printed enhanced usual care reminders (EUCRs)
Number of subjects: 3547
Study 19362800 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced letter reminders
Number of subjects: 3547
Study 17186430 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative nasogastric or nasojejunal tube (Tube Group, n = 43)
Number of subjects: 84
Study 17186430 — intervention group
Group type: COMPARATOR
Intervention: No tube (No‐tube Group, n = 41)
Number of subjects: 84
Study 15076014 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg adjunctive mirtazapine
Number of subjects: 24
Study 15076014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11222419 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led unit
Number of subjects: 238
Study 11222419 — intervention group
Group type: COMPARATOR
Intervention: Usual post-acute care
Number of subjects: 238
Study 9759798 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg bid
Number of subjects: 343
Study 9759798 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 500 microg qid
Number of subjects: 343
Study 9759798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study 9759798 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg bid and Terbutaline 500 microg qid
Number of subjects: 343
Study 9759798 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 343
Study 7827322 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (40 mg)
Number of subjects: 4
Study 7827322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 7827322 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 4
Study 30835436 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate (0.40 g/kg)
Number of subjects: 7
Study 30835436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 28233458 — intervention group
Group type: COMPARATOR
Intervention: β-blocker treatment
Number of subjects: 5242
Study 28233458 — intervention group
Group type: COMPARATOR
Intervention: β1-/β2-receptor-blockers (n=2219)
Number of subjects: 5242
Study 28233458 — intervention group
Group type: COMPARATOR
Intervention: High-dose β-blockers (>25 mg carvedilol equivalent daily dose, n=1005)
Number of subjects: 5242
Study 26254013 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniaturized multiplane TEE probe
Number of subjects: 57
Study 26254013 — intervention group
Group type: COMPARATOR
Intervention: Standard TEE probe
Number of subjects: 57
Study 23757424 — intervention group
Group type: EXPERIMENTAL
Intervention: EX50 (50% VO2peak)
Number of subjects: 11
Study 23757424 — intervention group
Group type: EXPERIMENTAL
Intervention: EX65 (65% VO2peak)
Number of subjects: 11
Study 23757424 — intervention group
Group type: EXPERIMENTAL
Intervention: EX50
Number of subjects: 11
Study 23757424 — intervention group
Group type: COMPARATOR
Intervention: EX65
Number of subjects: 11
Study 23757424 — intervention group
Group type: COMPARATOR
Intervention: CON (control trial)
Number of subjects: 11
Study 21270723 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential injection of 1.5% mepivacaine followed 90 secs later by 0.5% ropivacaine
Number of subjects: 103
Study 21270723 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous injection of 1.5% mepivacaine and 0.5% ropivacaine
Number of subjects: 103
Study 19922129 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 19
Study 19922129 — intervention group
Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 19
Study 16509104 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive meaningless gestures applied to RHDP with neglect
Number of subjects: 40
Study 16509104 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive meaningless gestures applied to RHDP without neglect
Number of subjects: 40
Study 16509104 — intervention group
Group type: COMPARATOR
Intervention: Passive meaningless gestures applied to LHDP
Number of subjects: 40
Study 16509104 — intervention group
Group type: COMPARATOR
Intervention: Passive meaningless gestures applied to controls
Number of subjects: 40
Study 12599012 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc-anti-CD66 mAb BW 250/183
Number of subjects: 12
Study 12599012 — intervention group
Group type: COMPARATOR
Intervention: (99m)Tc-anti-CD45 mAb YTH 24.5
Number of subjects: 12
Study 10689268 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium (30 mg/kg)
Number of subjects: 28
Study 10689268 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 28
Study 9577225 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain patients
Number of subjects: 0
Study 9577225 — intervention group
Group type: COMPARATOR
Intervention: Student control group
Number of subjects: 0
Study 9577225 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric patients
Number of subjects: 0
Study 8451143 — intervention group
Group type: EXPERIMENTAL
Intervention: Massed Practice group (no rests)
Number of subjects: 24
Study 8451143 — intervention group
Group type: COMPARATOR
Intervention: Distributed Practice group (1 min. rest after each 1 min. of viewing)
Number of subjects: 24
Study 8451143 — intervention group
Group type: EXPERIMENTAL
Intervention: Massed Practice group
Number of subjects: 24
Study 8451143 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributed Practice group
Number of subjects: 24
Study 8451143 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys in Trial 3
Number of subjects: 24
Study 8451143 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigidity scores
Number of subjects: 24
Study 3534847 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0
Study 3534847 — intervention group
Group type: EXPERIMENTAL
Intervention: Canrenoate potassium
Number of subjects: 0
Study 3534847 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0
Study 30174281 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg
Number of subjects: 252
Study 30174281 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg
Number of subjects: 252
Study 29933529 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM)
Number of subjects: 100
Study 29933529 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium diclofenac (SD)
Number of subjects: 100
Study 29933529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 25465826 — intervention group
Group type: EXPERIMENTAL
Intervention: Meteorological events classified as temperature changes in the 7 days prior to AHF event.
Number of subjects: 7141
Study 22338035 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA meal
Number of subjects: 10
Study 22338035 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA meal
Number of subjects: 10
Study 22338035 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA meal
Number of subjects: 10
Study 22338035 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFAs
Number of subjects: 10
Study 20384753 — intervention group
Group type: EXPERIMENTAL
Intervention: KTP laser treatment
Number of subjects: 0
Study 20384753 — intervention group
Group type: COMPARATOR
Intervention: Electrocoagulation (EC) treatment
Number of subjects: 0
Study 18413464 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum urate concentration (top quintile)
Number of subjects: 804
Study 18413464 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum urate concentration (men)
Number of subjects: 804
Study 18413464 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum urate concentration (women)
Number of subjects: 804
Study 18413464 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in striatal [(123)I]beta-CIT uptake
Number of subjects: 804
Study 15716163 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 0
Study 15716163 — intervention group
Group type: EXPERIMENTAL
Intervention: First-degree biological relatives of schizophrenia patients
Number of subjects: 0
Study 15716163 — intervention group
Group type: COMPARATOR
Intervention: Nonpsychiatric controls
Number of subjects: 0
Study 12012078 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (5 mg x day(‐1))
Number of subjects: 10
Study 12012078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10426452 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent docetaxel (Taxotere) 100 mg/m2 every 3 weeks
Number of subjects: 0
Study 10426452 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy regimens (mitomycin C plus vinblastine, methotrexate plus 5‐fluorouracil, or 5‐fluorouracil plus vinorelbine)
Number of subjects: 0
Study 10426452 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent docetaxel
Number of subjects: 0
Study 10426452 — intervention group
Group type: COMPARATOR
Intervention: Single-agent doxorubicin
Number of subjects: 0
Study 7472542 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy on the recently symptomatic artery
Number of subjects: 659
Study 7472542 — intervention group
Group type: COMPARATOR
Intervention: Medically treated patients with an occluded contralateral artery
Number of subjects: 659
Study 7472542 — intervention group
Group type: COMPARATOR
Intervention: Medically treated patients with mild-to-moderate contralateral artery stenosis
Number of subjects: 659
Study 7472542 — intervention group
Group type: COMPARATOR
Intervention: Patients with an occluded contralateral artery
Number of subjects: 659
Study 7472542 — intervention group
Group type: COMPARATOR
Intervention: Patients with mild-to-moderate contralateral stenosis
Number of subjects: 659
Study 1690970 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 50
Study 1690970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 1690970 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (after 4 additional weeks)
Number of subjects: 50
Study 477212 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol ingestion
Number of subjects: 32
Study 477212 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary ethanol measurement
Number of subjects: 32
Study 31538401 — intervention group
Group type: EXPERIMENTAL
Intervention: StandingTall exercise program delivered through tablet computers for 12 weeks
Number of subjects: 15
Study 31763287 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle turbinate resection (Group I)
Number of subjects: 31
Study 31763287 — intervention group
Group type: COMPARATOR
Intervention: No middle turbinate resection (Group II)
Number of subjects: 31
Study 28183567 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyromental height measurement test (TMH)
Number of subjects: 451
Study 28183567 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyromental distance measurement test (TMD)
Number of subjects: 451
Study 28183567 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Mallampati test (MMT)
Number of subjects: 451
Study 28183567 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper lip bite test (ULBT)
Number of subjects: 451
Study 28183567 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation difficulty scale (IDS)
Number of subjects: 451
Study 28183567 — intervention group
Group type: EXPERIMENTAL
Intervention: Cormack-Lehane scores (C‐L)
Number of subjects: 451
Study 24755729 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TMS (n = 7)
Number of subjects: 19
Study 24755729 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (n = 11)
Number of subjects: 19
Study 25069199 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60
Study 25069199 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 60
Study 22188311 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily topiramate
Number of subjects: 76
Study 22188311 — intervention group
Group type: COMPARATOR
Intervention: Pre-emptive frovatriptan
Number of subjects: 76
Study 19958429 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% niacinamide plus 1% N-undecylenoyl phenylalanine formulation
Number of subjects: 140
Study 19958429 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% niacinamide formulation
Number of subjects: 140
Study 19958429 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 140
Study 17572907 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic Doppler echocardiography (TTDE) with adenosine (140 gamma/kg/min x 3-6 min)
Number of subjects: 5
Study 17572907 — intervention group
Group type: COMPARATOR
Intervention: Doppler-wire (DW) with intracoronary adenosine (40 gamma bolus)
Number of subjects: 5
Study 15320674 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GI carbohydrate (CHO) - honey (GI = 35)
Number of subjects: 9
Study 15320674 — intervention group
Group type: EXPERIMENTAL
Intervention: High GI carbohydrate (CHO) - dextrose (GI = 100)
Number of subjects: 9
Study 15320674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 15320674 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO condition (combined low and high GI)
Number of subjects: 9
Study 15320674 — intervention group
Group type: COMPARATOR
Intervention: Dextrose vs. placebo
Number of subjects: 9
Study 15320674 — intervention group
Group type: COMPARATOR
Intervention: Honey vs. placebo
Number of subjects: 9
Study 15320674 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose treatment
Number of subjects: 9
Study 15320674 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey treatment
Number of subjects: 9
Study 15320674 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate (HR) and rate of perceived exertion (RPE)
Number of subjects: 9
Study 11282700 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy (DBT) for 20 weeks
Number of subjects: 31
Study 11282700 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list comparison condition for 20 weeks
Number of subjects: 31
Study 9274581 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 1018
Study 9274581 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (antianginal drugs)
Number of subjects: 1018
Study 9274581 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 1018
Study 9274581 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 1018
Study 8055799 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of iodized salt
Number of subjects: 1080
Study 8055799 — intervention group
Group type: COMPARATOR
Intervention: No iodized salt
Number of subjects: 1080
Study 8055799 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine iodine concentration
Number of subjects: 1080
Study 8055799 — intervention group
Group type: EXPERIMENTAL
Intervention: Goiter prevalence
Number of subjects: 1080
Study 8055799 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 1080
Study 3103436 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate, 7.5 mg/kg of body weight
Number of subjects: 20
Study 3103436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31281981 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous perineural local anesthetic infusion (CPI) with ropivacaine 0.2% administered at 2 mL/h for 72 hours
Number of subjects: 93
Study 31281981 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%) administered at 2 mL/h for 72 hours
Number of subjects: 93
Study 31281981 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CPI and placebo)
Number of subjects: 93
Study 29924041 — intervention group
Group type: EXPERIMENTAL
Intervention: Galgeun-tang-ga-cheongung-sinyi (GGTCS)
Number of subjects: 58
Study 29924041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 27475032 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based intervention promoting adherence to controller medication (two computer-delivered sessions based on motivational interviewing combined with text message reminders)
Number of subjects: 49
Study 27475032 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 49